Equity Overview
Price & Market Data
Price: $2.26
Daily Change: -$0.084 / 3.72%
Daily Range: $2.22 - $2.57
Market Cap: $192,908,576
Daily Volume: 9,808,841
Performance Metrics
1 Week: -13.88%
1 Month: 13.25%
3 Months: 16.75%
6 Months: 30.92%
1 Year: 21.77%
YTD: -4.03%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.